This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kaklamani, V.G., Vaiopoulos, G., and Kaklamanis, P.G., 1998, Behçet’ss disease. Semin. Arthritis Rheum. 27: 197–217.
Yazici, H., 2002, Behçet’ss syndrome: Where do we stand? Am. J. Med. 112: 75–76.
Kaklamani, V.G., and Kaklamanis, P.G., 2001, Treatment of Behcet’s disease: an update. Semin. Arthritis Rheum. 30: 299–312.
Sfikakis, P.P., Theodossiadis, P.G., Katsiari, C.G., et al., 2001, Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358: 295–296.
Goossens, P.H., Verburg, R.J., and Breedveld, F.C., 2001, Remission of Behçet’s syndrome with tumor necrosis factor alpha blocking therapy. Ann. Rheum. Dis. 60: 637.
Robertson, L.P., and Hickling, P., 2001, Treatment of recalcitrant orogenital ulceration of Behçet’s syndrome with infliximab. Rheumatology (Oxford) 40: 473–474.
Hassard, P.V., Binder, S.W., Nelson, V., et al., 2001, Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: a case report. Gastroenterology 120: 995–999.
Travis, S.P., Czajkowski, M., McGovern, D.P., et al., 2001, Treatment of intestinal Beihçet’s syndrome with chimeric tumor necrosis factor alpha antibody. Gut 49: 725–728.
Munoz-Fernandez, S., Hidalgo, V., Fernandez-Melon, J., et al., 2001, Comment on ref. 5. Lancet 358: 1644.
Gul, A., 2001, Behçet’s disease: an update on the pathogenesis. Clin. Exp. Rheumatol. 19 (suppl 24): S6–12.
Turan, B., Gallati, H., Erdi, H., et al., 1997, Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet’s disease: soluble TNFR-75 as a biological marker of disease activity. J. Rheumatol. 24: 128–132.
Evereklioglu, C., Er, H., Turkoz, Y., et al., 2002, Serum levels of TNF-α sIL-2R, IL-6 and IL-8 are increased and associated with elevated lipid per oxidation in patients with Behcet’s disease. Mediators Inflamm. 11: 87–93.
Chronopoulou, H., Tzavara, V., Oikonomopoulos, N., et al., 2001, High levels of TNF-α in the aqueous humor in patients suffering from Adamantiades-Behcet’s disease: Preliminary results. Invest. Ophth. Vis. Sci. 42 (suppl 4): S708.
Santos Lacomba, M., Marcos Martin, C., Gallardo Galera, J.M., et al., 2001, Aqueous humor and serum tumor necrosis factor-α in clinical uveitis. Ophthalmic Res. 33: 251–255.
Rosenbaum, M., Rosner, I., and Portnoy, E., 2002, Remission of Behcet’s syndrome with TNF-α blocking treatment. Ann. Rheum. Dis. 61: 283–284.
Sfikakis, P.P., 2002, Behcet’s disease: a new target for anti-TNF treatment. Ann. Rheum. Dis. 61 (suppl II): 1151–1153.
Day R., 2002, Adverse reactions to TNF-a inhibitors in rheumatoid arthritis. Lancet 359: 540–541.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Katsiari, C.G., Theodossiadis, P.G., Kaklamanis, P.G., Markomichelakis, N.N., Sfikakis, P.P. (2004). Successful Long-term Treatment of Refractory Adamantiades-Behçet’ss Disease (ABD) with Infliximab: Report of Two Patients. In: Zouboulis, C.C. (eds) Adamantiades-Behçet’s Disease. Advances in Experimental Medicine and Biology, vol 528. Springer, Boston, MA. https://doi.org/10.1007/0-306-48382-3_111
Download citation
DOI: https://doi.org/10.1007/0-306-48382-3_111
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-47757-7
Online ISBN: 978-0-306-48382-0
eBook Packages: Springer Book Archive